nach oben

World Journal of Surgery

Erschienen in:

01.04.2014

Does “Conversion Chemotherapy” Really Improve Survival in Metastatic Colorectal Cancer Patients with Liver-Limited Disease?

verfasst von: K. Kataoka, A. Kanazawa, S. Iwamoto, T. Kato, A. Nakajima, A. Arimoto

Erschienen in: World Journal of Surgery | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The clinical benefits of conversion chemotherapy followed by liver resection for initially unresectable colorectal liver metastases are still controversial. The criteria for unresectability vary from one team to another. To clarify this issue, we retrospectively assessed the survival and characteristics of metastatic colorectal cancer (mCRC) patients with liver-limited disease (LLD) who underwent conversion therapy.

Method

Our criteria for resectability depended on the size of the remnant liver volume (>30 %) and expected function after removal of all metastases. Between December 2007 and September 2011, a total of 115 patients were diagnosed as having mCRC with LLD and received chemotherapy. Among them, 47 had tumors that were initially diagnosed as resectable. They underwent hepatic resection after chemotherapy (resected group). Of the 67 tumors were initially diagnosed as unresectable, 12 became resectable after chemotherapy (conversion group), leaving 55 tumors that remained unresectable after chemotherapy (unresected group).

Results

The median follow-up was 25.2 months. Hepatic resection was more invasive in the conversion group than in the resected group. Median disease-free survival was significantly higher in the resected group than in the conversion group (p = 0.013). Overall survival (OS) was also higher in the resected group, but the difference was not significant (p = 0.36). However, OS was significantly higher in the conversion group than in the unresected group (p = 0.034). Multivariate analysis of the resected and conversion groups showed that OS was significantly negatively influenced by abnormal carcinoembryonic antigen levels at surgery (p = 0.037) and a hospital stay >30 days (p = 0.009).

Conclusions

Our results showed that conversion chemotherapy could contribute to longer OS in mCRC patients with LLD.

Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRef

Stangl R, Altendorf-Hoffman A, Charnley RM et al (1994) Factors influencing the natural history of colorectal liver metastasis. Lancet 343:1405–1410PubMedCrossRef

Leonard GD, Brennner B, Kernery NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastasis from colorectal carcinoma. J Clin Oncol 23:2038–2048PubMedCrossRef

Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCentralPubMedCrossRef

Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657 (discussion 657–658)PubMedCentralPubMedCrossRef

Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522PubMedCentralPubMedCrossRef

Masi G, Cupini S, Marcucci L et al (2006) Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 13:58–65PubMedCrossRef

Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47PubMedCrossRef

Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417PubMedCrossRef

10.

Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671PubMedCrossRef

11.

Masi G, Loupakis F, Pollina L et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249:420–425PubMedCrossRef

12.

Garufi C, Torsello A, Tumolo S et al (2010) Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103:1542–1547PubMedCentralPubMedCrossRef

13.

Skof E, Rebersek M, Hlebanja Z et al (2009) Capecitabine plus irinotecan (XELIRI regimen) compared to 5-FU/LV plus irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 9:120PubMedCentralPubMedCrossRef

14.

Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRef

15.

Douillard JY, Siena S, Cassidy J et al (2010) Randomized phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705PubMedCrossRef

16.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef

17.

Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706–3712PubMedCrossRef

18.

Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016PubMedCentralPubMedCrossRef

19.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

20.

Sobin LH, Wittekind C (2002) TNM classification of malignant tumours. Wiley, Hoboken

21.

Mangram AJ, Horan TC, Pearson ML et al (1999) Guideline for prevention of surgical site infection, 1999: Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20:250–278 (quiz 279–280)PubMedCrossRef

22.

Anonymous (1999) National Cancer Institute Common Toxicity Criteria, Version 2.0. Bethesda, National Cancer Institute. Cited: November 20, 2012

23.

Clavien PA, Barkun J, de Oliviera ML et al (2009) The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196PubMedCrossRef

24.

Adam R, Hoti E, Bredt LC (2010) Evolution of neoadjuvant therapy for extended hepatic metastases: have we reached our (non-resectable) limit? J Surg Oncol 102:922–931PubMedCrossRef

25.

Xu J, Qin X, Wang J et al (2011) Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol 137:1379–1396PubMedCrossRef

26.

Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol 27:1829–1835PubMedCrossRef

27.

Lam VW, Spiro C, Laurence JM et al (2012) A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19:1292–1301PubMedCrossRef

28.

Alberts SR (2012) Update on the optimal management of patients with colorectal liver metastases. Crit Rev Oncol Hematol 84:59–70PubMedCrossRef

29.

Zdenkowski N, Chen S, van der Westhuizen A et al (2012) Curative strategies for liver metastases from colorectal cancer: a review. Oncologist 17:201–211PubMedCentralPubMedCrossRef

30.

Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311–1319PubMedCrossRef

31.

Poston GJ, Adam R, Alberts S et al (2005) OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23:7125–7134PubMedCrossRef

32.

Charnsangavej C, Clary B, Fong Y et al (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13:1261–1268PubMedCrossRef

33.

De Haas RJ, Wicherts DA, Flores E et al (2008) R1 resection by necessity for colorectal liver metastases: Is it still a contraindication to surgery? Ann Surg 248:626–637PubMed

34.

Bodingbauer M, Tamandl D, Schmid K et al (2007) Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg 94:1133–1138PubMedCrossRef

35.

Dexiang Z, Li R, Ye W et al (2012) Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases. Ann Surg Oncol 19:2860–2868PubMedCrossRef

36.

Kataoka K, Kanazawa A, Nakajima A et al (2013) The feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study. Surg Today 43:1154–1161PubMedCrossRef

37.

Scheele J, Stangl R, Altendorf-Hoffmann A et al (1995) Resection of colorectal liver metastases. World J Surg 19:59–71. doi:10.1097/SLA.0b013e3182356236 PubMedCrossRef

38.

Jaeck D, Bachellier P, Guiguet M et al (1997) Long-term survival following resection of colorectal hepatic metastases: Association Francaise de Chirurgie. Br J Surg 84:977–980PubMedCrossRef

39.

Adam R, Pascal G, Azoulay D et al (2003) Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 238:871–883 (discussion 883–884)PubMedCentralPubMedCrossRef

40.

Cauchy F, Aussilhou B, Dokmak S et al (2012) Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 256:746–752PubMedCrossRef

41.

Abdalla EK (2010) Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 102:960–967PubMedCrossRef

42.

Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:450–493CrossRef

43.

Wright AS, Sampson LA, Warner TF et al (2005) Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 236:132–139PubMedCrossRef

44.

Narita M, Oussoultzoglou E, Jaeck D et al (2011) Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 98:1463–1475PubMedCrossRef

Titel: Does “Conversion Chemotherapy” Really Improve Survival in Metastatic Colorectal Cancer Patients with Liver-Limited Disease?
verfasst von: K. Kataoka
A. Kanazawa
S. Iwamoto
T. Kato
A. Nakajima
A. Arimoto
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: World Journal of Surgery / Ausgabe 4/2014
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-013-2305-1

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Candidates for Limited Lateral Neck Dissection among Patients with Metastatic Papillary Thyroid Carcinoma

Management of Anastomotic Leak: Lessons Learned from a Large Colon and Rectal Surgery Training Program

Ratio Between Proximal/Distal Gastroesophageal Reflux Does Not Discriminate Abnormal Proximal Reflux

Stroke Volume Response to Liver Graft Reperfusion Stress in Cirrhotic Patients

Teaching the Management of Surgical Emergencies Through a Short Course to Surgical Residents in East/Central Africa Delivers Excellent Educational Outcomes

Perioperative Immunonutrition in Surgical Cancer Patients: A Summary of a Decade of Research

Update Chirurgie